Last update May 1, 2022


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

R-Isomer of Lansoprazole with similar pharmacokinetics. It is a proton pump inhibitor (PPI) with actions and uses similar to those of omeprazole. It is indicated in the treatment of peptic ulcer and gastroesophageal reflux. Oral administration once daily.

At latest update, relevant information on excretion into breast milk was not found.

Its pharmacokinetic data (very high percentage of protein binding, very wide volume of distribution and short half-life) make it highly unlikely that significant quantities will pass into breast milk.

Both Omeprazole and Pantoprazole, from the same pharmacological group (PPI) and with similar pharmacokinetic characteristics, are excreted in insignificant amounts in breast milk.

Since it's neutralized by the acid pH of stomach, capsules with enteric coated granules are used. Because of this, it is thought that the small quantity of Lansoprazole that may reach the breast milk would be neutralized by infant's stomach. In addition, absorption is greatly decreased by the presence of food. 

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.


  • Famotidine (Safe substance and/or breastfeeding is the best option.)
  • Nizatidine (Safe substance and/or breastfeeding is the best option.)
  • Omeprazole (Safe substance and/or breastfeeding is the best option.)
  • Pantoprazole (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dexlansoprazole is also known as

Dexlansoprazole in other languages or writings:


Main tradenames from several countries containing Dexlansoprazole in its composition:


Variable Value Unit
Molecular weight 369 daltons
Protein Binding 96 - 99 %
VD 0.58 l/Kg
pKa 9.35 -
Tmax 4 (1 - 6) hours
1 - 2 hours


  1. Ashfaq M, Haroon MZ, Alkahraman YM. Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders. Endocr Regul. 2022 Apr 30;56(2):134-147. Abstract Full text (link to original source)
  2. Dexlansoprazole. Drug Summary. 2014 Full text (in our servers)
  3. Dexlansoprazol. Ficha técnica. 2010 Full text (in our servers)
  4. Olsen KM, Hitzeman ML. Dexlansoprazole MR in the Management of Gastroesophageal Reflux Disease Clinical Medicine: Therapeutics 2009:1 1641–1652. 2009 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM